Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | MicrobiomeTrials
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-05Est. Completion: 2033-09-19
Enrollment target: 50 participants
Locations
Novartis Investigative Site, Sydney, New South Wales, Australia